Article
Computational study on the molecular mechanisms of drug resistance of Narlaprevir due to V36M, R155K, V36M+R155K, T54A, and A156T mutations of HCV NS3/4A protease.
Biochemistry and cell biology = Biochimie et biologie cellulaire - 1 Oct 2014
Wang Huiqun, Geng Lingling, Chen Bo-Zhen, Ji Mingjuan
Abstract excerpt
Narlaprevir is a novel NS3/4A protease inhibitor of hepatitis C virus (HCV), and it has been tested in a phase II clinical trial recently. However, distinct drug-resistance of Narlaprevir has been discovered. In our study, the molecular mechanisms of drug-resistance of Narlaprevir due to the mutations V36M, R155K, V36M+R155K, T54A, and A156T of NS3/4A protease have been investigated by molecular dynamics (MD)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.